Stephen T. Oh, MD, PhD, discusses patients who would be suitable to receive pacritinib for myelofibrosis, highlighting data showing correlation between transfusion independence and reduction in bone marrow reticulin fibrosis.
Case: A 63-Year-Old Man with Myelofibrosis
Clinical Presentation:
Follow up and Clinical Workup at 3 Months:
Follow up and Clinical Workup at 6 Months:
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More